This is a working overview of unapproved substance, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-04 and is reviewed periodically as new material appears.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic PPARδ agonist | Not a steroid or a selective androgen receptor modulator. |
| Common synonyms | Cardarine, GW501516, GW-501516, endurobol | Names vary by supplier and literature source. |
| Appearance | White to off-white powder | Consistent with many small-molecule research chemicals. |
| Solubility | Low in water; soluble in DMSO and ethanol | Often prepared in organic solvent for laboratory work. |
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid and energy metabolism. |
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
The European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) (formerly EFCC) is a federation of national member societies of clinical chemistry and laboratory medicine from Europe. EFLM has its registered office in Brussels and its administrative office in Milan. EFLM is the European Regional member of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
== Side effects == Clinical studies have found that deramciclane is well-tolerated in humans at dosages ranging between 0.2–150 mg. All reported side effects were mild-moderate with the most common side effect being headache and dizziness. No severe side effects were reported in any clinical trial, and no side effects were found to be dose-dependent. Trial participants showed no significant increases in liver enzyme activity and no changes in ECGs, systolic blood pressure, diastolic blood pressure, HDL cholesterol, or LDL cholesterol levels. Another advantage to deramciclane is that it did not produce any withdrawal effects after long-term studies, like other anxiolytics do.
As such, PBPK modeling can be used, inter alia, to evaluate the involvement of carrier-mediated transport, clearance saturation, enterohepatic recirculation of the parent compound, extra-hepatic/extra-gut elimination; higher in vivo solubility than predicted in vitro; drug-induced gastric emptying delays; gut loss and regional variation in gut absorption.
Sources: en.wikipedia.org
=== Bibliography === "Annex A – Estate Baseline – 2009" (PDF). Defence Estates Development Plan (DEDP) 2009. GOV.UK (Report). Ministry of Defence. 3 July 2009. Retrieved 30 March 2023. Halley, James J (1988). RAF Squadrons. The Squadrons of the Royal Air Force & Commonwealth 1918–1988. Tonbridge, UK: Air Britain (Historians). ISBN 0-85130-164-9. Jackson, Paul (1986). Britain's Armed Forces Today: 4 RAF Germany. Shepperton, UK: Ian Allan. ISBN 0-7110-1579-1. Jefford, C. G. (1988). RAF Squadrons. A comprehensive record of the movement and equipment of all RAF squadrons and their antecedents since 1912. Shrewsbury, UK: Airlife. ISBN 1-85310-053-6. Langford, F. (1991). The Dorset Year Book - 1991. Dorset, UK: The Society Of Dorset Men. March, Peter R. (1992). Royal Air Force Yearbook 1992. Fairford, UK: Royal Air Force Benevolent Fund. March, Peter R. (1998). Royal Air Force Yearbook 1998. Fairford, UK: Royal Air Force Benevolent Fund. Sturtivant, Ray; Hamlin, John (2007). Royal Air Force flying training and support units since 1912. Tonbridge, UK: Air-Britain (Historians). ISBN 978-0851-3036-59.
The decay of radon-222 was once reported to exhibit large 4% peak-to-peak seasonal variations (see plot), which were proposed to be related to either solar flare activity or the distance from the Sun, but detailed analysis of the experiment's design flaws, along with comparisons to other, much more stringent and systematically controlled, experiments refute this claim.
== Global demand == Global EO demand has expanded from 16.6 Mt (18.3 million short tons) in 2004 to 20 Mt (22 million short tons) in 2009, while demand for refined EO expanded from 4.64 Mt (5.11 million short tons) in 2004 to 5.6 Mt (6.2 million short tons) in 2008. In 2009, demand is estimated to have declined to about 5.2 Mt (5.7 million short tons). Total EO demand registered a growth rate of 5.6% per annum during the period 2005 to 2009 and is projected to grow at 5.7% per annum during 2009 to 2013.
Alexei Sayle (born 7 August 1952), English actor, author, stand-up comedian, television presenter and former recording artist; voted the 18th greatest stand-up comic of all time on Channel 4's 100 Greatest Stand-Ups in 2007; In an updated 2010 poll he came 72nd. has written two short story collections, five novels, including a graphic novel and a radio series spin-off book, as well as columns for various publications; has written for Time Out and the Sunday Mirror; was one of eight contributory authors to the BBC Three competition End of Story. Simon Schama (born 13 February 1945), author of Lithuanian Jewish ancestry, specialising in art history, Dutch history, Jewish history, and French history. He is a University Professor of History and Art History at Columbia University, New York. Isaac Schapera FBA FRAI (23 June 1905 Garies, Cape Colony – 26 June 2003 London, England); of South African Jewish-Russian Jewish ancestry; author of numerous highly regarded anthropology books and over 200 monographs and scholarly academic papers on Africa;social anthropologist at London School of Economics specialising in South Africa; notable for his ethnographic and typological studies of the indigenous peoples of Botswana and South Africa; one of the founders of group that would develop British social anthropology, and students included important figures of anthropology, such as Ernest Gellner, Eileen Krige, Hilda Kuper, Max Gluckman, John Comaroff, Johan Frederik Holleman and Jean Comaroff.
Sources: en.wikipedia.org
Based on evidence from the geologic record, life most likely emerged on Earth between 4.32 and 3.48 Gya. In 2017, the earliest physical evidence of life was reported to consist of microbialites in the Nuvvuagittuq Greenstone Belt of Northern Quebec, in banded iron formation rocks at least 3.77 and possibly as old as 4.32 Gya. The micro-organisms could have lived within hydrothermal vent precipitates, soon after the 4.4 Gya formation of oceans during the Hadean. The microbes resemble modern hydrothermal vent bacteria, supporting the view that abiogenesis began in such an environment. Later research disputed this interpretation of the data, stating that the observations may be better explained by abiotic processes in silica-rich waters, "chemical gardens," circulating hydrothermal fluids, or volcanic ejecta. Biogenic graphite has been found in 3.7 Gya metasedimentary rocks from southwestern Greenland and in microbial mat fossils from 3.49 Gya cherts in the Pilbara region of Western Australia. Evidence of early life in rocks from Akilia Island, near the Isua supracrustal belt in southwestern Greenland, dating to 3.7 Gya, have shown biogenic carbon isotopes. In other parts of the Isua supracrustal belt, graphite inclusions trapped within garnet crystals are connected to the other elements of life: oxygen, nitrogen, and possibly phosphorus in the form of phosphate, providing further evidence for life 3.7 Gya.
In 2014, the European Association for Palliative Care recommended oxycodone by mouth as a second-line alternative to morphine by mouth for cancer pain. In children between 11 and 16, the extended-release formulation is FDA-approved for the relief of cancer pain, trauma pain, or pain due to major surgery (for those already treated with opioids, who can tolerate at least 20 mg per day of oxycodone) – this provides an alternative to Duragesic (fentanyl), the only other extended-release opioid analgesic approved for children. Oxycodone, in its extended-release form or in combination with naloxone, is sometimes used off-label in the treatment of severe and refractory restless legs syndrome.
Gastrointestinal system: nausea, vomiting, abdominal pain, and diarrhea Central nervous system: headache Whole body: fever, phlebitis or thrombophlebitis, complications at the intravenous cannulation site (e.g. induration), unspecified pain, flu-like syndrome, myalgia, chills, and paresthesia Respiratory: dyspnea Renal: increased plasma creatinine Hematological: anemia Electrolytes: hypokalemia Liver: increased liver enzymes (asymptomatic) Hypersensitivity: rash, facial edema, pruritus Other: tachycardia Additionally, infrequent cases of symptomatic liver damage, peripheral edema and swelling, and hypercalcemia have been seen.
== Procedure == Add 1 ml of concentrated HNO3 to 1 ml of the test sample. Gently heat the mixture and cool it. Slowly add sodium hydroxide (NaOH, 40 % w/v in water) solution until the mixture becomes alkaline and a colour change is observed. If the colour changes from yellow to orange, this indicates the presence of an aromatic amino acid. When human skin or nails are exposed to nitric acid, they turn yellow after some time, indicating the presence of protein. The finger nails show a bright yellow colour (finger nails are made up of keratin, which is a protein) which cannot be scraped off, unlike the yellow colouration on the skin, which can be peeled off.
The Sanitary Commission for the Eradication of Hookworm Disease was a Rockefeller-funded campaign from 1909 to 1914 to study and treat hookworm disease in 11 Southern states. Hookworm was known as the "germ of laziness". In 1913, the foundation expanded its work with the Sanitary Commission abroad and set up the International Health Division (also known as International Health Board), which began the foundation's first international public health activities. The International Health Division conducted campaigns in public health and sanitation against malaria, yellow fever, and hookworm in areas throughout Europe, Latin America and the Caribbean including Italy, France, Venezuela, Mexico, and Puerto Rico, totaling fifty-two countries on six continents and twenty-nine islands. The first director was Wickliffe Rose, followed by F.F. Russell in 1923, Wilbur Sawyer in 1935, and George Strode in 1944. A number of notable physicians and field scientists worked on the international campaigns, including Lewis Hackett, Hideyo Noguchi, Juan Guiteras, George C. Payne, Livingston Farrand, Cornelius P. Rhoads, and William Bosworth Castle. In 1936, The Rockefeller Foundation received one of the first awarded Walter Reed Medals from The American Society of Tropical Medicine & Hygiene to recognize its study and control of Yellow Fever. The World Health Organization, seen as a successor to the IHD, was formed in 1948, and the IHD was subsumed by the larger Rockefeller Foundation in 1951, discontinuing its overseas work.
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.
It binds to and activates PPARδ, a nuclear receptor that regulates genes related to fatty acid oxidation and energy use. This activation alters transcription in tissues such as skeletal muscle and liver. The full range of downstream effects in humans is not fully established.
No, cardarine is not known to occur naturally in plants, animals, or humans. It is a synthetic molecule produced for laboratory research. Products labeled as cardarine should therefore be treated as manufactured chemicals with variable purity.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.